Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting

Ljungberg, Börje,Professor,1949-Umeå universitet,Urologi och andrologi (författare)

Background Recently, the CARMENA and SURTIME studies, suggested that upfront cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and high-risk metastatic renal cell carcinoma (mRCC). However, CN remains an indication in low-risk and when immediate systemic treatment is not required. The aim was to evaluate the long-term overall survival (OS) in patients with primary mRCC, based on the first line treatment. Methods There were 1483 patients with primary mRCC in the National Kidney Cancer Registry from 2005 to 2013. Data on primary treatment, TNM stage, RCC type, tumor size, patient age and sex were extracted. Survival time was calculated from time of diagnosis to time of death or until July 2019. Mann-Whitney U and Chi-square tests, the Kaplan-Meyer method and Cox regression analyses were used. Results Patients primary treated with CN had a significantly longer OS (p < .001) than patients primary treated with systemic therapy or palliation. In a Cox regression multivariate analysis, the hazard ratio for CN compared with no CN was 1.600, 95%Ci (1.492 - 1.691),p < .001. Also occurrence of lymph node metastases, T-stage, patients age and year of diagnosis, remained as independent predictors of OS. Conclusion Patients primary treated with CN survived significantly longer than patients primary treated with systemic therapy or palliation, in all age groups. CN was an important first-line treatment option in mRCC patients.

Sundqvist, Pernilla,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology(Swepub:oru)pst (författare)
Lindblad, Per,1953-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Urology(Swepub:oru)pld (författare)
Kjellman, A.Karolinska Institutet (författare)
Thorstenson, A.Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (författare)
Hellström, Mikael,1950Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiologi,Institute of Clinical Sciences, Department of Radiology,Department of Radiology, Sahlgrenska Academy, Gothenburg University, and Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:gu)xhelmi (författare)
Kröger Dahlin, Britt-IngerUmeå universitet,Urologi och andrologi(Swepub:umu)dinbrr00 (författare)
Thomasson, MarcusUmeå universitet,Onkologi(Swepub:umu)math0013 (författare)
Harmenberg, U.Department of Oncology, Karolinska University Hospital/Karolinska Institute, Stockholm, Sweden (författare)
Lundstam, Sven,1944Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology,Department of Urology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden(Swepub:gu)xlusvl (författare)
Umeå universitetUrologi och andrologi (creator_code:org_t)

Ingår i:Scandinavian Journal of Urology: Medical Journals Sweden AB54:6, s. 487-4922168-18052168-1813

Av författaren/redakt...: Ljungberg, Börje ...; Sundqvist, Perni ...; Lindblad, Per, 1 ...; Kjellman, A.; Thorstenson, A.; Hellström, Mikae ...; visa fler...; Kröger Dahlin, B ...; Thomasson, Marcu ...; Harmenberg, U.; Lundstam, Sven, ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Urologi och njur ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Av lärosätet: Göteborgs universitet; Örebro universitet; Umeå universitet; Karolinska Institutet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.